I am a social and health psychologist whose program of behavioral research examines psychosocial aspects of cancer prevention and control. Specifically, my research aims to translate advances in genetics and genomics into improvements in patient care and public health. I am interested in understanding how people perceive, adapt to, and make decisions regarding uncertain health risk information, such as the information that people can receive through genetic and genomic testing. I am currently leading studies to assess how patients and their families respond to inherited risk information that is revealed as part of tumor sequencing (e.g., the MSK-IMPACT™ test), to evaluate alternative models for offering genetic counseling and testing to patients with cancer, and to examine the effects of novel breast cancer genetic risk feedback on patients’ decision-making, psychological, and behavioral outcomes.
I co-lead the Genomics, Risk & Health Decision Making Laboratory in Memorial Sloan Kettering’s Behavioral Sciences Service. The mission of this laboratory is to optimize the translation of novel discoveries regarding cancer risk and genomics, through research concerning cancer risk perceptions and health decision-making in patients, families, healthcare providers, and members of the general public across diverse populations and settings. Our laboratory also provides training and mentorship to students, fellows, and junior faculty involved in this research. In addition, I have a secondary appointment in the Clinical Genetics Service of the Department of Medicine, where I am affiliated with the clinical genetics laboratory of Dr. Kenneth Offit.
I am a member of various scientific societies including the American Society of Human Genetics, American Society of Preventive Oncology, Society of Behavioral Medicine, and Society for Health Psychology. I am also a member of the Survivorship, Outcomes and Risk Program at Memorial Sloan Kettering.
Education: PhD, Stony Brook University; MPH, Columbia University
Fellowships: National Cancer Institute
Department & Service: Department of Psychiatry and Behavioral Sciences, Behavioral Sciences Service; Department of Medicine, Division of Solid Tumor Oncology, Clinical Genetics Service
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jada G. Hamilton discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.